Articles

An innovation for the allergy market

A strongly decreased dose of the active ingredient budesonide in Budesolv, compared to Rhinocort Aqua, shows pronounced efficacy after first application, validating the Marinosolv platform
Brought to you byDDNews Staff
| 2 min read

VIENNA—A pivotal Phase 3 study for Budesolv has provided Marinomed Biotech AG, a global biopharmaceutical company headquartered in Vienna, with clinical validation of the efficacy of its innovative Marinosolv technology platform. The available data proves that after one week of treatment, Budesolv 10µg achieves at least the same effect with a dose six times lower than Rhinocort Aqua 64µg, the current marketed reference product.

Budesolv is a new formulation of the compound budesonide based on Marinomed’s Marinosolv platform. Whereas currently marketed steroid nasal sprays for allergic rhinitis contain the active compounds as largely undissolved suspensions, Marinosolv enables the substance to be fully dissolved.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.